
Unicycive Therapeutics (UNCY) Stock Forecast & Price Target
Unicycive Therapeutics (UNCY) Analyst Ratings
Bulls say
Unicycive Therapeutics is a promising clinical-stage biotechnology company with upcoming potential catalysts such as FDA inspection completion, potential U.S. approval for its phosphate binder OLC, and potential TDAPA designation for OLC. Despite potential launch delays, the company's expenses and timetable adjustments support a positive outlook with a new 12-month price target of $15 per diluted share, down from $22.
Bears say
Unicycive Therapeutics is facing several key fundamental risks that negatively impact its stock outlook. Notably, there are concerns regarding the company's financials, such as its high levels of R&D and G&A expenses, non-cash stock compensation, and net losses. Furthermore, the company faces significant commercial risks related to potential delays in FDA approval and adoption of its key product candidate, OLC, in the hyperphosphatemia market, as well as competition from other approved binders. And while the company has a promising product pipeline, it has a history of operating losses and may not achieve profitability for multiple periods as it invests in its pre-commercial infrastructure for a potential OLC launch.
This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares